Yueying Niu,1 Mengqing Cao,1 Shumin Li,1 Juanfen Mo,2 Ziyi Zhu,1 Haiqin Wang1 1Department of Respiratory Medicine, The Second Hospital of Jiaxing, Jiaxing, Zhejiang, People’s Republic of China; 2The Key Laboratory, The Second Hospital of Jiaxing, Jiaxing,
Cao M, Li S, Zhu Z, Mo J, Wang H, Niu Y
core
Direct healthcare cost comparison of fluticasone/salmeterol and budesonide/formoterol maintenance and reliever therapy for moderate to severe asthma in the South African public sector. [PDF]
Leong TD, Besada D.
europepmc +1 more source
Real-World Outcomes across Baseline Risk Profiles in Patients with COPD Initiating Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate in Spain: Insights from the ORESTES Study. [PDF]
Alcázar-Navarrete B +15 more
europepmc +1 more source
Treatment patterns of eosinophilic esophagitis in the biologic era-a real-world analysis. [PDF]
Pokryszka J +11 more
europepmc +1 more source
Beyond the Wheeze: Incidental Diagnosis of Eosinophilic Oesophagitis in a Young Child With Asthma-Like Symptoms. [PDF]
Tabassum S +3 more
europepmc +1 more source
A case of adrenal insufficiency after initiation of targeted-release budesonide formulation (Nefecon) in a patient with IgA nephropathy. [PDF]
Laxamana TD +3 more
europepmc +1 more source
Efficacy of Yupingfeng powder in the treatment of bronchial asthma in adults: a systematic review and meta-analysis. [PDF]
Zhang Q +5 more
europepmc +1 more source
New Horizons in IgA Nephropathy: Approach to Current and Emerging Therapies. [PDF]
Madhavaram SK +3 more
europepmc +1 more source
Efficacy and safety of as-needed albuterol-budesonide versus albuterol in patients with asthma aged 12 to <18 years: design of the randomised, double-blind, parallel-group phase IIIb ACADIA trial. [PDF]
Bacharier LB +7 more
europepmc +1 more source

